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Original Article
Clostridium difficile infection increases acute and chronic
morbidity and mortality
Margaret A. Olsen PhD1,2, Dustin Stwalley MS1, Clarisse Demont PhD3 and Erik R. Dubberke MD1
1Department of Medicine, Washington University School of Medicine, St Louis, Missouri, 2Department of Surgery, Washington University School of Medicine,
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Abstract
Objective: In this study, we aimed to quantify short- and long-term outcomes of Clostridium difficile infection (CDI) in the elderly,
including all-cause mortality, transfer to a facility, and hospitalizations.
Design: Retrospective study using 2011 Medicare claims data, including all elderly persons coded for CDI and a sample of uninfected
persons. Analysis of propensity score-matched pairs and the entire population stratified by the propensity score was used to determine the
risk of all-cause mortality, new transfer to a long-term care facility (LTCF), and short-term skilled nursing facility (SNF), and subsequent
hospitalizations within 30, 90, and 365 days.
Results: The claims records of 174,903 patients coded for CDI were compared with those of 1,318,538 control patients. CDI was associated
with increased risk of death (odds ratio [OR], 1.77; 95% confidence interval [CI], 1.74–1.81; attributable mortality, 10.9%), new LTCF
transfer (OR, 1.74; 95% CI, 1.67–1.82), and new SNF transfer (OR, 2.52; 95% CI, 2.46–2.58) within 30 days in matched-pairs analyses. In a
stratified analysis, CDI was associated with greatest risk of 30-day all-cause mortality in persons with lowest baseline probability of CDI
(hazard ratio [HR], 3.04; 95% CI, 2.83–3.26); the risk progressively decreased as the baseline probability of CDI increased. CDI was also
associated with increased risk of subsequent 30-day, 90-day, and 1-year hospitalization.
Conclusions: CDI was associated with increased risk of short- and long-term adverse outcomes, including transfer to short- and long-term
care facilities, hospitalization, and all-cause mortality. The magnitude of mortality risk varied depending on baseline probability of CDI,
suggesting that even lower-risk patients may benefit from interventions to prevent CDI.
(Received 15 June 2018; accepted 30 August 2018; electronically published 9 November 2018)
Clostridium difficile is the most common microorganism asso-
ciated with death in persons with gastroenteritis1,2 and the single
most common organism responsible for US healthcare-associated
infections.3 Although C. difficile infection (CDI) is clearly asso-
ciated with morbidity and mortality, the incremental impact of
CDI on mortality is not clear. In a 2015 review of CDI outcomes,
all-cause mortality ranged from 11.8% to 38%, and attributable
mortality ranged from 0% to 16.7%, depending on the time frame
to assess mortality, statistical methods, and whether the investi-
gations were conducted during endemic or epidemic periods of
CDI.4 A prior review of European studies found similar hetero-
geneity in all-cause hospital mortality (4%–37%) and CDI-
attributable mortality (0%–23%).5
Variation in all-cause and attributable CDI mortality is also
likely due to differences in patient populations. Because CDI
incidence and risk of complicated infection are much higher in
the elderly than in younger persons,2,6,7 focus on outcomes in the
elderly is important. Recently, 2 studies reported CDI mortality in
the elderly using Medicare data. Drozd et al8 found 1.9% 30-day
attributable mortality after hospital-onset CDI, although their
analysis included younger beneficiaries (ie, end-stage renal dis-
ease, disabled). Shorr et al9 reported attributable CDI mortality of
14.9% at 60 days and 19.2% at 1 year in the elderly. Prior studies
estimating the risk of mortality due to CDI have not considered
the possibility of effect modification, in which the risk is not
uniform but varies depending on other factors.10
The data on CDI-attributable morbidity are even more limited
than data for mortality. Adults with CDI in a managed care plan
were at higher risk of subsequent hospitalization, intensive care
unit stay, and emergency department utilization than enrollees
without CDI, particularly if they had recurrent CDI.11 Patients
with CDI have been shown to be at increased risk of short- and
longer-term hospital readmission,8,12–14 and discharge to a nur-
sing care facility after hospitalization.15
We used Medicare data to better understand the impact of
CDI on all-cause mortality, short-term morbidity, and long-term
morbidity in the elderly. We performed 2 different analyses to
estimate differential risk of outcomes in CDI compared to
uninfected persons, pooled across all persons and within strata of
CDI risk. We used this approach to determine whether
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heterogeneity in risk of poor outcomes exists because it may
impact how CDI prevention efforts should be targeted.
Methods
We obtained data for CDI patients from 2010–2012 Medicare
claims data for all persons coded for CDI in 2011. For control
patients, we used the 2010–2012 5% random sample Medicare
data, excluding persons coded for CDI in 2011.16 Long-term care
facility (LTCF) stays were identified using the 2010–2012 mini-
mum data set (MDS), which includes standardized assessments of
patients in nursing facilities that accept federal payment.17
Eligible patients were those aged ≥66 years with complete
Medicare fee-for-service enrollment during the 12 months prior
to the CDI (and control) index date. Persons with no claims in
2010 and 2011 were excluded to ensure use of health benefits.
Patients coded for CDI in the last quarter of 2010 were excluded
to restrict the population to individuals newly diagnosed in 2011.
Index date
Patients coded for CDI (International Classification of Disease,
Ninth Revision, Clinical Modification [ICD-9-CM] diagnosis code
008.45) were identified from January 1, 2011, through December
31, 2011, in the inpatient, outpatient, carrier (ie, physician), or
skilled nursing facility (SNF) files. The CDI onset date was
assigned as described previously,18 and an analogous index date
was randomly selected for control patients such that the dis-
tribution of index dates among control patients mirrored the
distribution of CDI index dates.19 The first episode of CDI in
2011 was used for all analyses.
Outcomes
All-cause mortality within 1 year was identified using the death
date in the Beneficiary Summary file. Secondary outcomes
included new transfer to an LTCF, new transfer to an SNF, and 1
or more hospitalizations within 30 days, 90 days, and 1 year after
the index date. New transfer to a SNF was identified using the
Medicare SNF file. LTCF residence was identified using method 2
described by Goodwin et al,20 that is, using the SNF file and MDS
to distinguish long-term from short-term SNF encounters.17,20
For new transfers to SNF and LTCF, patients were excluded if
they met the definition for these encounters in the year prior to
the index date.
Acute-care hospitalizations with admission date after the index
date were identified using the inpatient file. For individuals
hospitalized on their index date, same-day transfers to another
hospital were excluded because they were not new hospitaliza-
tions. A subsequent hospitalization to treat CDI in patients
diagnosed as an outpatient was considered a new hospitalization.
Covariates
Risk factors for CDI in the year prior to the index date were
identified using ICD-9-CM diagnosis, Current Procedural Ter-
minology, 4th edition, and uniform billing revenue codes. Risk
factors included comorbidities, infections, and healthcare expo-
sures, as defined previously,19 and acute noninfectious conditions
and frailty indicators (Appendix Table 1). Acute noninfectious
conditions included conditions expected to require hospitaliza-
tion or outpatient treatment that may result in antibiotic exposure
(Appendix Table 1). Frailty indicators were conditions associated
with declining health (eg, decubitus ulcer, difficulty walking)
(Appendix Table 1). Comorbidities were identified as recom-
mended by Klabunde et al,21 whereas acute conditions required
only a single code.
Statistical analysis
Descriptive statistics were performed using the χ2 and Mann–
Whitney U tests. To create the propensity score, we used multi-
variable logistic regression with the dependent variable CDI and
independent variables in Appendix Table 2. To calculate the
probability of CDI at the index date, the independent variables
were assessed in the year prior. The logit of the propensity score
was used to match cases and controls 1:1 without replacement,
using a caliper of 0.2 times the standard deviation of the logit of
the propensity score.22,23 Standardized differences for all covari-
ates were calculated before and after matching, with values >0.1
indicating imbalance (Appendix Fig. 1).24,25
We used the McNemar test to compare mortality, LTCF, and
SNF transfer, with calculation of odds ratios for matched pairs.
For the LTCF analysis the population was restricted prior to
matching to exclude individuals previously residing in a LTCF
and individuals hospitalized at their index date who died during
the hospitalization, because they would not have the opportunity
for an LTCF transfer. The population was restricted similarly for
the SNF analysis. Attributable risk was calculated in the matched
pairs by subtraction of the percentage of controls with outcome
from the percentage of CDI cases with outcome. For analysis of
subsequent hospitalizations, Cox proportional hazards models
were performed with a robust variance estimator to account for
the matching.26
For stratified analyses, the probabilities were divided into 20
strata (ie, ventiles), based on the propensity score in the CDI
group to obtain approximately equal numbers of CDI cases across
strata for analysis of mortality, which resulted in variable num-
bers of control patients per stratum. For secondary analyses,
because individuals were excluded based on specific criteria, the
numbers of CDI cases were no longer equal across strata. Ana-
lyses were performed using Cox proportional hazards models,
with CDI the only independent variable, stratified by the pro-
pensity score ventiles. SAS version 9.4 software (SAS Institute,
Cary, NC) was used for all analyses. The Washington University
Human Research Protection Office approved this research with a
waiver of informed consent.
Results
The population of fee-for-service Medicare beneficiaries aged 66
and older included 1,510,046 persons. Of these, 16,605 were
excluded due to CDI diagnosed in the last quarter of 2010,
resulting in a final population of 1,493,441 persons for analysis:
174,903 coded for CDI and 1,318,538 control patients. Extra-
polation to the entire 2011 fee-for-service Medicare population
with at least 1 healthcare claim in 2010–2011 resulted in a
comparison population of ~ 26.4 million and an estimated CDI
incidence of 663 per 100,000 elderly persons.
The mean age of the study population was 77.5 years; 925,316
patients (62.0%) were women; and 1,301,397 patients (87.1%)
were white (Table 1). Also, 271,128 patients (18.2%) had dual
eligibility in Medicare and Medicaid, indicative of low
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socioeconomic status. Residence in an LTCF prior to the index
date was identified in 95,775 (6.4%), and 404,227 (27.1%) had
been hospitalized at least once in the prior year.
A total of 169,073 patients (11.3%) died within 1 year of the
CDI (control) index date. The all-cause mortality rates were
40.9% among CDI patients and 7.4% for control patients. Of the
persons eligible for new LTCF and SNF, 23,700 of 1,381,830
(1.72%) became residents in an LTCF (7.39% of CDI and 1.17% of
control patients) and 119,780 of 1,429,750 (8.38%) entered an
SNF (37.52% of CDI and 5.48% of control patients) within 1 year.
Of the patients who newly entered an LTCF, 5,598 (23.6%) were
also resident in an SNF before transitioning to the LTCF. Of
patients newly resident in an LTCF, 23% died within 1 year of the
CDI (control) onset date; of patients newly resident in an SNF,
33.4% died within 1 year. The population eligible for subsequent
hospitalization(s) included individuals whose CDI or control
index dates occurred as outpatients, or for those hospitalized at
their index date, those patients who were alive at hospital dis-
charge (n= 1,474,999). At least 1 hospitalization within 30, 90,
and 365 days after the index date occurred in 76,691 patients
(23.21% of CDI and 3.03% of control patients) within 30 days
after the index date, in 162,022 patients (39.91% of CDI and
7.50% of control patients) within 90 days, and in 369,931 patients
(58.93% of CDI and 21.00% of control patients) within 1 year.
CDI was associated with a 1.77-fold increased risk of 30-day
all-cause mortality (95% confidence interval [CI], 1.74–1.81) in
the propensity-score matched pairs analysis, and attributable
mortality risk of 10.9% (Table 2 and Appendix Table 3). In sec-
ondary analyses, CDI was associated with a 1.74-fold increased
risk of new LTCF transfer (95% CI, 1.67–1.82; attributable risk,
2.7%) and a 2.52-fold increased risk of new SNF entry (95% CI,
2.46–2.58; attributable risk, 15.8%) within 30 days (Table 2).
Matching was successful in 128,406 of 174,903 of the CDI cases
(73.4%). The standardized differences and distribution of pro-
pensity scores are shown in Appendix Figures 1 and 2. Unmat-
ched CDI cases were older and had higher frequencies of virtually
all risk factors, consistent with the propensity score distribution
for CDI cases (Appendix Table 2 and Figure 2).
The results of the stratified analysis for all-cause mortality are
shown in Figure 1. The risk of mortality was highest in patients
with the lowest likelihood of CDI (ventile 1: HR, 3.04; 95% CI,
2.83–3.26), and this risk progressively decreased as the probability
of CDI increased. In the highest-risk stratum, the risk of mortality
was much lower but was still statistically significant (ventile 20:
HR, 1.09; 95% CI, 1.01–1.17). As can also be seen in Figure 1, the
percentage of CDI and control patients who died within 1 year
progressively increased with increasing probability of CDI, from
8.8% of CDI cases and 3.0% of control patients in ventile 1, to
64.2% of CDI cases and 59.7% of control patients in ventile 20
with the highest probability of CDI.
The same pattern was identified for new LTCF (Fig. 1) and
SNF transfers (Appendix Fig. 3). The highest risk of both out-
comes occurred in the first stratum with lowest likelihood of CDI
(LTCF: HR, 3.86; 95% CI, 3.20–4.65 and SNF: HR, 4.51; 95% CI,
4.17–4.89). The risk of both outcomes decreased with increasing
likelihood of CDI, albeit not as dramatically as mortality.
We analyzed 121,830 matched pairs for risk of acute-care
hospitalizations. CDI was associated with increased risk of hos-
pitalization within 30 days (HR, 2.27; CI, 2.22–2.32), within
90 days (HR, 1.95; CI, 1.92–1.98), and within 1 year (HR, 1.52; CI,
1.51–1.54), with attributable risk ranging from 11.4% to 15.7%
(Table 2, Appendix Table 4). Similar results were obtained in the
Table 1. Demographics and Other Characteristics of the Medicare Elderly Population
Characteristic
Total







Age, mean y (SD) 77.5 (7.9) 80.5 (8.0) 77.1 (7.7)
Female 925,316 (62.0) 112,251 (64.2) 813,065 (61.7)
Race
White 1,301,397 (87.1) 153,857 (88.0) 1,147,540 (87.0)
Black 110,870 (7.4) 13,801 (7.9) 97,069 (7.4)
Other race 81,174 (5.4) 7,245 (4.1) 73,929 (5.6)
Prior LTCF residence 95,775 (6.4) 40,143 (23.0) 55,632 (4.2)
Dual eligibility for Medicare and Medicaid 271,128 (18.2) 56,376 (32.2) 214,752 (16.3)
Acute-care hospitalization in the previous year 404,227 (27.1) 148,066 (84.7) 256,161 (19.4)
SNF encounter in previous year 183,539 (12.3) 93,595 (53.5) 89,944 (6.8)
Note. LTCF, long-term care facility; SNF, skilled-nursing facility.
Table 2. Outcomes Attributable to CDI in Propensity Score-Matched Pairs
Analyses in the Elderly Medicare Population
Outcome OR (95% CI)a Risk Difference, %
Mortality within 1 y 1.77 (1.74–1.81) 10.9
New transfer to LTCF within 1 y 1.74 (1.67–1.82) 2.7
New transfer to SNF within 1 y 2.52 (2.46–2.58) 15.8
Acute-care hospitalization
Within 30 d 2.27 (2.22–2.32) 11.4
Within 90 d 1.95 (1.92–1.98) 15.7
Within 1 y 1.52 (1.51–1.54) 12.4
Note. CDI, Clostridium difficile infection; OR, odds ratio; CI confidence interval; LTCF, long-
term care facility; SNF, skilled nursing facility.
aHazard ratios presented for acute-care hospitalizations.
Infection Control & Hospital Epidemiology 67
stratified analyses (Fig. 2 and Appendix Fig. 4). The percentage of
cases with at least 1 subsequent hospitalization was consistently
higher for CDI cases across all strata compared to control
patients. The risk of hospitalization was highest in individuals in
the lowest risk stratum and progressively decreased with
increasing baseline probability of CDI. The magnitude of differ-
ence with increasing baseline CDI probability was greatest for
30-day hospitalization.
Discussion
Using 2011 Medicare data, we found 10.9% excess 30-day mor-
tality in CDI cases matched on the probability of CDI to control
patients, with odds of mortality of 1.8. In stratified analysis, the
risk of mortality was highest in persons with lowest probability of
CDI, with progressively decreased risk of mortality as the prob-
ability of CDI increased. The minimal contribution of CDI to risk
of mortality in the strata with highest baseline CDI probability
Fig. 1. Stratified hazard ratios and rates of outcomes within 1 year after Clostridium difficile infection (CDI) or control index date. Outcomes are (A) mortality, (B) new entry into
a long-term care facility. The bars represent the respective event rates in controls (open bars) and CDI cases (grey bars).
Hazard ratio and 95% confidence interval.
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makes clinical sense because patients at very high risk of CDI also
have very high underlying severity of illness, with 60% 1-year
mortality among the control uninfected patient population in the
highest stratum. In contrast, patients in the lowest baseline CDI
stratum had a 3-fold increased risk of 1-year all-cause mortality if
they developed CDI. The stratified analysis demonstrates that the
increased risk of mortality associated with CDI is not uniform in
all elderly persons.
In matched-pairs analysis, the attributable risk of 30-day LTCF
transfer due to CDI was 2.7%, and the attributable risk of 30-day
SNF transfer due to CDI was much higher at 15.8%. In contrast to
prior studies, we developed algorithms to distinguish long-term
care residence (ie, nursing home) from short-term care stays to
determine the impact of CDI on these distinct outcomes. SNF
stays (median, 29 days), which reflect acute-care events requiring
additional medical care before patients can return home, are
reimbursed by Medicare for the purpose of rehabilitation fol-
lowing a hospitalization.27 In contrast, LTCF implies continual
residence with no transition back to the community. The
increased risk of 30-day SNF admission is suggestive of acute
CDI-attributable morbidity and is further supported by the
increased risk of 30- and 90-day hospitalizations in CDI patients.
The increased risk of LTCF transfer suggests that CDI also con-
tributes to chronic morbidity from which patients are unable to
fully recover. This increased risk of transition to a LTCF has
additional implications in terms of quality of life and economics;
these costs are largely borne out of pocket or by the Medicaid
program. The reduced impact of effect modification on these
outcomes suggests that CDI-attributable morbidity impacts
patients regardless of their underlying CDI risk.
The pooled CDI attributable mortality of 10.9% we calculated
using propensity score matched pairs is similar to the results
reported by Nanwa et al28 in a Canadian population. In that
study, the attributable risk of mortality due to community-onset
CDI was 13% at 1 year, although they did not report mortality
specifically in the elderly. In contrast, Kuntz et al11 reported much
lower attributable mortality risk of 4% due to nonrecurrent CDI
in adult Kaiser Health Plan members. One possible explanation
for the lower CDI mortality risk in the Kuntz et al study was the
requirement of a negative CDI test in control patients, thus
selecting for control patients suspected of having CDI with likely
higher underlying severity of illness than a nontested group.
Our results also differ from those of Shorr et al9 in the Medicare
elderly population, in which they reported higher attributable
mortality due to CDI of 10% at 30 days and 19% at 1 year.9
Although Shorr et al also used propensity scores and matched
pairs, they included fewer variables in their model and less
stringent methods for matching than we did in this study. Because
we were able to match only 73% of CDI cases to controls (vs 99%
by Shorr), our analysis consisted of patients likely more similar in
baseline characteristics, resulting in lower attributable risk than
that reported by Shorr et al.
The limitations of this study include use of administrative
data, which lack clinical detail concerning some CDI risk factors
(eg, antibiotic utilization), CDI verification, and medications used
to treat CDI in the hospital. Previously, we found the CDI ICD-9-
CM diagnosis code reported by hospitals to have a sensitivity of
78% and a specificity of 99.7% compared to C. difficile toxin assay
results.29 Although identification of CDI using claims data is
imperfect, the impact on our findings should be minimal because
the net effect of this misclassification results in bias toward the
null hypothesis. The use of older Medicare data is also a limita-
tion, and our results should be confirmed with more recent data
in which the incidence of CDI is lower. Despite the imperfection
Fig. 2. Stratified hazard ratios and rates of hospitalization within 30 days after Clostridium difficile infection (CDI) or control index date. The total number of patient included in
the hospitalization analyses was 1,475,045 (158,558 CDI case patients and 1,316,487 control patients) after excluding 18,396 persons who died during the index hospitalization.
The bars represent the hospitalization rates in control patients (open bars) and CDI case patients (grey bars).
Hazard ratio and 95% confidence interval. The null hazard ratio of 1.0 is indicated by the horizontal dashed line.
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of claims data, the CDI incidence of 663 per 100,000 we calculated
is almost identical to that reported by Lessa et al2 (628 per
100,000 elderly persons) using 2011 EIP surveillance data and
laboratory tests to identify CDI. To mitigate the lack of clinical
detail concerning prior antibiotic utilization, we included vari-
ables for a wide range of infections and classified them by
expected type and duration of antibiotic therapy.19 We also
included variables for numerous acute and chronic conditions
that may result in antibiotic treatment and healthcare exposure.
We calculated risk of outcomes based on exposures prior to the
CDI (control) index date to quantify the probability of CDI.
Although we have not considered subsequent exposures in this
study, variation in CDI treatment, and other conditions after the
index date, we used this method because we aimed to calculate
differing risks of outcomes after balancing baseline exposures
between the CDI and uninfected groups.
Strengths of this study include the very large population size,
including all elderly beneficiaries coded for CDI in 2011, and
generalizability of results to the Medicare fee-for-service popu-
lation. We included a comprehensive set of variables into the
propensity score model and achieved good balance in baseline
characteristics, ensuring comparable case and control patients for
the matched-pairs analyses. We performed a stratified analysis of
outcomes based on the propensity score; it demonstrated het-
erogeneity in the impact of CDI on mortality depending on
baseline CDI risk.
Overall, CDI was associated with increased risk of mortality,
new LTCF, and short-term SNF transfer within 30 days and 1
year in elderly persons. The increased mortality risk associated
with CDI was much greater in persons with low baseline CDI risk
and progressively decreased as the baseline risk of CDI increased.
The increased risk of SNF and LTCF admissions, as well as 30-day
and 1-year hospitalization, demonstrates that CDI negatively
impacts patients in both the short and long terms. Our findings
suggest that CDI prevention strategies should not be limited to
just high-risk populations; lower-risk elderly populations may
have the greatest benefit. New strategies to prevent CDI focused
on the elderly need to be developed to reduce mortality, mor-
bidity, and decline resulting in loss of independence and
institutionalization.
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